Yao Deng1, Hao Wan1, Jianbo Tian1, Xiang Cheng2, Meilin Rao1, Jiaoyuan Li3, Hongli Zhang1, Ming Zhang1, Yimin Cai1, Zequn Lu1, Yue Li1, Siyuan Niu1, Na Shen3, Jiang Chang1, Zemin Fang4, Rong Zhong1. 1. Department of Epidemiology & Biostatistics & Ministry of Education Key Lab of Environment & Health, School of Public Health, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei 430030, PR China. 2. Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430022, PR China. 3. Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, PR China. 4. Division of Cardiothoracic & Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, PR China.
Abstract
Aim: To identify patients with colorectal cancer (CRC) who are at a truly higher risk of progression, which is key for individualized approaches to precision therapy. Materials & methods: We developed a predictor associated with progression-free interval (PFI) using The Cancer Genome Atlas CRC methylation data. Results: The risk score was associated with PFI in the whole cohort (p < 0.001). A nomogram consisting of the risk score and other significant clinical features was generated to predict the 3- and 5-year PFI in the whole set (area under the curve: 0.79 and 0.71, respectively). Conclusion: The risk score based on 23 DNA-methylation sites may serve as the basis for improved prediction of progression in patients with CRC in future clinical practice.
Aim: To identify patients with colorectal cancer (CRC) who are at a truly higher risk of progression, which is key for individualized approaches to precision therapy. Materials & methods: We developed a predictor associated with progression-free interval (PFI) using The Cancer Genome Atlas CRC methylation data. Results: The risk score was associated with PFI in the whole cohort (p < 0.001). A nomogram consisting of the risk score and other significant clinical features was generated to predict the 3- and 5-year PFI in the whole set (area under the curve: 0.79 and 0.71, respectively). Conclusion: The risk score based on 23 DNA-methylation sites may serve as the basis for improved prediction of progression in patients with CRC in future clinical practice.
Authors: Min Zhou; Shasha Hong; Bingshu Li; Cheng Liu; Ming Hu; Jie Min; Jianming Tang; Li Hong Journal: Front Genet Date: 2021-09-09 Impact factor: 4.772